Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) President Joshua Isner sold 1,291 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $642.43, for a total transaction of $829,377.13. Following the completion of the transaction, the president now owns 181,892 shares in the company, valued at approximately $116,852,877.56. This trade represents a 0.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Joshua Isner also recently made the following trade(s):
- On Tuesday, November 12th, Joshua Isner sold 20,000 shares of Axon Enterprise stock. The shares were sold at an average price of $606.15, for a total transaction of $12,123,000.00.
Axon Enterprise Stock Down 4.1 %
Shares of Axon Enterprise stock opened at $609.96 on Thursday. Axon Enterprise, Inc. has a 1 year low of $241.72 and a 1 year high of $698.67. The firm has a market cap of $46.51 billion, a price-to-earnings ratio of 157.61, a PEG ratio of 14.19 and a beta of 1.01. The company has a 50-day moving average of $551.82 and a 200 day moving average of $412.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on AXON
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Quent Capital LLC increased its holdings in shares of Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 75 shares in the last quarter. Prestige Wealth Management Group LLC increased its stake in Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 44 shares in the last quarter. Blue Trust Inc. raised its holdings in Axon Enterprise by 987.5% in the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after buying an additional 79 shares during the last quarter. Brooklyn Investment Group bought a new position in shares of Axon Enterprise in the third quarter worth approximately $41,000. Finally, Planning Capital Management Corp grew its holdings in shares of Axon Enterprise by 83.3% during the third quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 55 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Recommended Stories
- Five stocks we like better than Axon Enterprise
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Investing in Commodities: What Are They? How to Invest in Them
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Manufacturing Stocks Investing
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.